Open an account

GeneDx Holdings

WGS · NASDAQ

$68.74+$2.45 (+3.70%)TodayMarket closed ·
Prev close $66.29

About WGS

GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,300 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

Employees
1,300
Headquarters
Stamford, Connecticut
Listed
Sep 4, 2020
Sector
Health Care
Industry
Health Care Providers & Services
Website
sema4.com

WGS key statistics

Market cap
2.05B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
831.14K
Volume
719.51K
Open price
$66.52
High today
$70.87
Low today
$66.01
52 Week high
$170.87
52 Week low
$32.21

GeneDx Holdings (WGS) at a glance

GeneDx Holdings (WGS) last traded at $68.74, with a market cap of 2.05B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $66.01 and $70.87. The current price is 4.1% above the day's low and 3.0% below its high.

Volume so far is 719.51K shares, in line with the average of 831.14K shares a day.

Over the past year GeneDx Holdings has ranged from $32.21 to $170.87, and now sits 26% of the way up that range.

GeneDx Holdings met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.01 per share against an estimate of -$0.1894.

The average analyst price target is $94.22, 37.1% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $94.22
Low
$74.74
Now
$68.74
High
$108.15

WGS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 184.4% on average.

  1. Q3 FY24: reported $0.04 per share against an estimate of -$0.2172
  2. Q4 FY24: reported $0.62 per share against an estimate of $0.1641
  3. Q1 FY25: reported $0.27 per share against an estimate of $0.0581
  4. Q2 FY25: reported $0.50 per share against an estimate of $0.103
  5. Q3 FY25: reported $0.49 per share against an estimate of $0.4271
  6. Q4 FY25: reported $0.14 per share against an estimate of $0.1125
  7. Q1 FY26: reported -$0.28 per share against an estimate of -$0.0101
  8. Q2 FY26: reported $0.01 per share against an estimate of -$0.1894

WGS news

  • Press releaseBusiness Wire

    GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis

  • Press releaseBusiness Wire

    GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

  • Press releaseBusiness Wire

    GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026

  • Press releaseBusiness Wire

    GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care

  • Press releaseBusiness Wire

    GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

  • Press releaseBusiness Wire

    GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree

  • Erica Kollmann

    Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside

  • Press releaseBusiness Wire

    GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Similar companies

Companies in the same industry as GeneDx Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.